Apogee Therapeutics to Participate in Upcoming November Investor Conferences

Company Overview - Apogee Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel biologics for inflammatory and immunology (I&I) markets, targeting conditions such as atopic dermatitis (AD), asthma, and chronic obstructive pulmonary disease (COPD) [3] - The company aims to address limitations of existing therapies by utilizing advanced antibody engineering to optimize efficacy and dosing [3] Product Pipeline - Apogee's most advanced program, APG777, is being developed for the treatment of atopic dermatitis, which is identified as the largest and least penetrated market within I&I [3] - The company has four validated targets in its portfolio and is pursuing both monotherapies and combination therapies to achieve best-in-class efficacy [3] Upcoming Events - Apogee Therapeutics will participate in several investor conferences, including: - Guggenheim Inaugural Healthcare Innovation Conference on November 12, 2024, at 3:00 p.m. ET - Stifel 2024 Healthcare Conference on November 18, 2024, at 10:20 a.m. ET - Jefferies London Healthcare Conference on November 20, 2024, at 3:30 a.m. GMT / 10:30 a.m. ET - A live and archived webcast of these events will be available on the company's website [2]